Objectives: To determine the prevalence of macrolide and streptogramin resistance in Streptococcus mitis isolates from neutropenic patients and to identify mechanisms of macrolide and streptogramin resistance in resistant isolates.
Introduction
Viridans streptococci constitute a significant part of the normal flora of the oral cavity and are a potential source of bacteraemia in immunocompromised patients. Streptococcus oralis, Streptococcus sanguis and Streptococcus mitis have been reported as the leading causes of these infections. 1 In the past, viridans streptococci were considered to be uniformly susceptible to b-lactams and macrolides. However, the emergence of strains resistant to b-lactams and other antibiotics is a cause of concern and could compromise currently used prophylactic and therapeutic regimens. S. mitis is closely related to Streptococcus pneumoniae and there is enough evidence to show that there is extensive exchange of genetic information between these species. 2 In streptococci, resistance to macrolides is conferred either by methylases, encoded by erm genes that modify the ribosomal target of macrolides or by pumps, encoded by mef(A) genes, that efflux these antibiotics. Ribosomal methylation results in crossresistance to macrolide, lincosamide and streptogramin B antibiotics (MLS B phenotype) and can be expressed either constitutively or inducibly. In streptococci, MLS B resistance is mostly mediated by determinants belonging to the erm(B) class. Another methylase, first described in Streptococcus pyogenes, and then found to be extensively present in this species but rare in S. pneumoniae, is mediated by a gene originally called ermTR and belonging to the erm(A) class. 3, 4 Recently, mutations in 23S rRNA or ribosomal proteins leading to macrolide resistance in clinical isolates of S. pneumoniae have also been described. 4 Macrolide efflux is mediated by a membrane protein encoded by the mef(A) gene and is characterized by resistance to 14-and 15-membered ring macrolides, whereas 16-membered ring macrolides, lincosamides and streptogramins, remain active even after induction with erythromycin (M phenotype). 5 Gram-negative bacteria and some Gram-positive organisms, such as Enterococcus faecalis are intrinsically resistant to streptogramins. Acquired resistance to streptogramins is mostly found in staphylococci and Enterococcus faecium where it is usually due to the acquisition of extrinsic genes responsible for inactivation (vat and vgb genes) or efflux of streptogramin components (vga genes). 6 In S. pneumoniae, resistance to streptogramins is rare and has been related to ribosomal mutations such as an A2062C mutation in domain V of 23S rRNA, or to L22 and L4 protein mutations. 4, 7, 8 Few studies have investigated the macrolide resistance mechanisms in S. mitis, in particular in immunocompromised patients who are exposed to multiple courses of antimicrobial treatments. The purpose of this study is to determine the susceptibility to antibiotics of S. mitis isolated in the Tunisian Bone Marrow Transplant Centre in 2002 and to characterize the mechanisms of macrolide and streptogramin resistance in erythromycin-and pristinamycin-resistant strains.
Materials and methods

Bacterial strains
In 2002, 169 S. mitis isolates were obtained from 66 patients hospitalized at the Tunisian Bone Marrow Transplant Centre. Of these, 85% of strains were isolated from systematic nasopharyngeal specimens, 5% from the upper respiratory tract and 10% from other sites including blood cultures. In 2002, S. mitis represented 9.5% of the total and 2% of the blood culture isolates in our centre. Isolates were identified by API Rapid ID 32 Strep system (bioMérieux, La-Balme-Les-Grottes, France). Only isolates for which identification results were rated as typical were retained for the study. When multiple isolates were obtained for a single patient, duplicates were eliminated on the basis of identical patterns of antimicrobial susceptibility. The following strains were used as controls in PCR: six S. mitis strains susceptible to erythromycin, S. pneumoniae HM28 containing the erm(B) gene, S. pneumoniae O2J1175 containing the mef(A) gene and S. aureus BM3002 containing vga(A), vgb(A) and vat(A) genes.
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Antibiotic susceptibility testing Susceptibility of S. mitis to penicillins, gentamicin, erythromycin, spiramycin, lincomycin and pristinamycin was tested by the agar diffusion technique using Mueller -Hinton medium (bioMérieux) supplemented with 5% horse blood and incubated at 378C for 24 h in an aerobic atmosphere under 5% CO 2 as recommended by the Comité de l'Antibiogramme de la Société Française de Microbiologie (CA-SFM).
11 Resistance to erythromycin, spiramycin and lincomycin indicated a cross MLS B resistance. Blunting of the lincomycin inhibition zone proximal to the erythromycin disc indicated an inducible dissociated MLS B resistance. Resistance to erythromycin and susceptibility to lincomycin with no blunting zone defined the M phenotype (efflux mechanism). The susceptibility of 120 erythromycin-resistant S. mitis to the following eight antibiotics was tested by the agar dilution technique: penicillin G (Biochemie GmbH, Vienna, Austria), ampicillin (Bristol-Myers Squibb S.P.A., Italy), erythromycin (Abbott, Rungis, France), lincomycin (Pfizer France, Paris, France), pristinamycin (Aventis, Vitry-sur-Seine, France), gentamicin (A. Menarini, Florence, Italy), vancomycin (Eli-Lilly France, S. A., Suresnes, France) and teicoplanin (Aventis).
11 MICs were determined on Mueller -Hinton agar supplemented with 5% horse blood and incubated at 378C for 24 h in an aerobic atmosphere under 5% CO 2 . An inoculum of 10 4 cfu per spot was used. S. pneumoniae CIP 104485 and E. faecalis ATCC 29212 were used as controls. Results were interpreted according to the recommendations of the CA-SFM.
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Polymerase chain reaction and sequencing
We used a multiplex PCR technique previously described which allowed amplification of erm(B), mef(A) and ermTR[erm(A)] genes. 9 For the strain resistant to pristinamycin, known streptogramin resistance genes belonging to the families of vat, vga and vgb genes were searched for by PCR as described. 12 In addition, for this strain, portions of rrl genes encoding 23S ribosomal RNA, and rplD and rplV genes encoding ribosomal proteins L4 and L22, respectively, were amplified. Analysis of the genomic sequence of S. mitis NCTC 12261, obtained at The Institute for Genomic Research website at http://www.tigr.org, allowed the design of 12 pairs of primers to amplify rrl, rplD and rplV genes. PCR products were sequenced on both strands. Oligonucleotide primers used are shown in Table 1 . The amino acid sequences of proteins L22 of the strain resistant to pristinamycin and of S. mitis NCTC 12261 were deduced from the sequence of the rplV gene and compared. Conserved regions in the protein L22 were identified by comparison with that of other Grampositive cocci, in particular S. pneumoniae.
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Results
MLS resistance
Of the 169 non-repetitive strains of S. mitis isolated in 2002, 70% (120 strains) were not susceptible to erythromycin and 83% to penicillin G whereas only 0.6% (one strain) was resistant to pristinamycin by the disc-diffusion technique. No strain was resistant to high levels of gentamicin or to vancomycin or teicoplanin. Three phenotypes were observed among the 120 erythromycin-resistant isolates. Fifty-eight strains (48.5%) displayed the cross MLS B resistance, five (4%) a dissociated MLS B resistance phenotype and 57 (47.5%) the M phenotype.
A summary of MIC range, MIC 50 and MIC 90 of seven antibiotics for erythromycin-resistant strains is listed in Table 2 . Teicoplanin was the most active antibiotic against erythromycinresistant strains with MIC 90 < 0.125 mg/L.
The pristinamycin-resistant strain (MIC = 2 mg/L) was intermediate to penicillin G (MIC = 1 mg/L) and resistant to erythromycin (MIC >1024 mg/L) and lincomycin (MIC = 512 mg/L).
Characterization of macrolide resistance in selected strains
Thirty-three erythromycin-resistant strains were studied further. Fourteen displayed the cross-MLS B resistance, five the dissociated MLS B phenotype and 14 the M phenotype. erm(B)-like sequences were amplified from the 19 strains with the MLS B phenotype. Five of these strains contained in addition mef(A)-like genes. The 14 strains with the M phenotype contained mef(A)-like genes. No DNA fragment could be amplified from the six erythromycin-susceptible S. mitis isolates with any of the primers tested. Distribution of erythromycin resistance genes according to erythromycin resistance phenotypes is reported in Table 3 . 
Characterization of resistance to pristinamycin
The strain resistant to pristinamycin contained an erm(B)-like gene. Neither vat, vga nor vgb genes conferring streptogramin resistance could be amplified by PCR. The analysis of the sequence of genes encoding the ribosomal structures which participate in the binding of streptogramins to their target did not reveal any mutation in the sequences of rrl and rplD genes. In contrast, comparison of the deduced amino acid sequences of the rplV genes of the pristinamycin-resistant strain and of S. mitis NCTC 12261 and S. pneumoniae R6 showed substitution of two amino acids in the L22 ribosomal protein, A105G and T108A, located at the conserved C terminus region of the protein 91 PRAKGSASPINKRTGHIAVAVAEKG 115 (substitutions underlined).
Discussion
In this study, the rates of non-susceptibility to penicillin G (83%) and macrolides (70%) are unusual and are remarkably higher than those reported in previous studies with viridans streptococci, 56.3% and 38% in the USA (from blood cultures), 19% and 32% in Germany (blood cultures in neutropenic patients), 43% and 38.5% in Greece (healthy children), 36.4% and 39.4% in Spain (blood cultures in neutropenic patients), 45% and 50% in Taiwan (S. mitis from infected sites), and 16.8% and 22.4% in Finland (elderly persons), respectively. 13 -18 However, in a Spanish study, 94.4% of healthy adult subjects and patients with pharyngitis carried one or more strains resistant to erythromycin. 19, 20 The high prevalence of penicillin and macrolide resistance in our study might be related to the particular population of patients included. Indeed, increasing incidence of resistance to antimicrobials has been documented in viridans streptococci isolated from neutropenic cancer patients. 14 In these patients, exposure to antimicrobials is high, resulting in the selection of resistant strains. Of note, S. mitis strains remained uniformly susceptible to teicoplanin and vancomycin.
In S. mitis, MLS B and M phenotypes were present at a similar frequency in our strains. This was also the case in a Spanish study. 19 However, the relative proportion of the two resistance phenotypes may vary according to the country or even within a given country. For instance, the M phenotype was found to be highly prevalent in another Spanish study and in Finland (80.6%).
18,20
Literature describing molecular mechanisms conferring resistance to macrolides in S. mitis is limited to a few reports. In our study, the molecular characterization of S. mitis clinical isolates revealed that the erm(B) and mef(A) genes are found with similar frequencies. Similar findings were reported in Spanish and Japanese studies with viridans streptococci. 19, 21 However, erm(B) was found more prevalent than mef(A) in a Canadian study whereas mef(A) genes were prevalent in a Spanish study. 20, 22 In our study, the MLS B and M phenotypes correlated with the presence of erm(B)-like and mef(A)-like genes, respectively. The strains resistant to erythromycin but susceptible to lincomycin which contained an erm(B)-like gene could be phenotypically distinguished from those with the M phenotype on the basis of resistance to spiramycin and antagonism between erythromycin and lincomycin. Strains carrying a mef(A)-like gene generally displayed lower MICs of erythromycin (4 -64 mg/L) than those with an erm(B)-like gene (MICs from 4 to >1024 mg/L) with some exceptions. Surprisingly, in five of 19 strains with the MLS B phenotype, the erm(B)-like gene was combined with a mef(A)-like gene, the M phenotype conferred by the latter gene being masked by the MLS B phenotype. Combination of both genes has already been detected in erythromycin-resistant S. pneumoniae and S. agalactiae, 9,23,24 but has not been previously found in S. mitis and has been reported in one study in only 0.8% of S. oralis. 19, 20, 22 Viridans streptococci have been suspected of being a possible reservoir of resistance genes and this accumulation of resistance genes in a non-negligible proportion of strains may contribute to rapid spread of resistance determinants to pathogenic species of streptococci. 2 We confirmed that streptogramin resistance is very uncommon in viridans streptococci. 16 The only strain resistant to pristinamycin contained an erm(B)-like gene which alone could not explain the streptogramin resistance. Indeed, the synergy is usually maintained between the factors A and B of the streptogramin combination despite the resistance to factor B conferred by the gene. 4 In contrast, the mutation that we found in the conserved C terminus of the L22 ribosomal protein might explain the streptogramin resistance. Mutations in the same conserved region and conferring resistance to streptogramins have been reported in clinical isolates and laboratory mutants of S. aureus 25 and S. pneumoniae. 7, 8 This is the only protein to interact with RNA sequences belonging to all six domains of 23S rRNA and is important for the folding of the 23S rRNA. It is also a partner of L4 in the probable formation of a gated opening for the tunnel exit. 7 This is the first report of L22 mutation in S. mitis.
